Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing.

[1]  D. Gerding,et al.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  E. Dubberke,et al.  Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Gerding,et al.  Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection , 2017, New England Journal of Medicine.

[4]  E. Dubberke,et al.  Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach , 2016, BMC Infectious Diseases.

[5]  L. Valiquette,et al.  Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Louie,et al.  Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Kristin E. Burke,et al.  Clostridium difficile Infection: A Worldwide Disease , 2014, Gut and liver.

[8]  T. Peto,et al.  Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile , 2013, The Journal of infectious diseases.

[9]  Daniel J. Wilson,et al.  Diverse sources of C. difficile infection identified on whole-genome sequencing. , 2013, The New England journal of medicine.

[10]  D. Gerding,et al.  Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Pamela Sears,et al.  Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.

[12]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[13]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[14]  J. Mossong,et al.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. , 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[15]  F. Barbut,et al.  Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.

[16]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .